Brain Sciences,
Journal Year:
2024,
Volume and Issue:
14(12), P. 1244 - 1244
Published: Dec. 12, 2024
Background
and
objective:
Staging
Parkinson’s
disease
(PD)
with
a
novel
simple
classification
called
MNCD,
based
on
four
axes
(Motor;
Non-motor;
Cognition;
Dependency)
five
stages,
correlated
severity,
patients’
quality
of
life
caregivers’
strain
burden.
Our
aim
was
to
apply
the
MNCD
in
advanced
PD
patients
treated
device-aided
therapy
(DAT).
Patients
Methods:
A
multicenter
observational
retrospective
study
first
start
levodopa-entacapone-carbidopa
intestinal
gel
(LECIG)
Spain
performed
(LECIPARK
study).
The
total
score
(from
0
12)
stages
1
5)
were
collected
by
neurologist
at
V0
(before
starting
LECIG)
V2
(follow-up
visit).
Wilcoxon’s
signed
rank
Marginal
Homogeneity
tests
applied
compare
changes
from
V2.
Results:
Sixty-seven
(58.2%
males;
69.9
±
9.3
years
old)
mean
duration
14.4
6.5
included.
treatment
(V2)
172.9
105.2
days.
At
V0,
classified
as
stage
2
(35.8%),
3
(46.3%)
or
4
(17.9%).
frequency
decreased
9%
(p
=
0.001).
6.27
1.94
5.21
2.23
<
0.0001).
From
V2,
motor
(M;
p
0.0001)
non-motor
symptom
(N;
burden
decreased,
autonomy
for
activities
daily
living
(D;
0.005)
improved.
Conclusions:
could
be
useful
classify
monitor
response
DAT.
